ChNPs can deliver anticancer drugs to thyroid carcinoma cells with greater selectivity by utilizing both active targeting through ligand-mediated interactions and passive targeting through the increased permeability and retention effect.
Abstract
Background: Systemic toxicity, poor drug selectivity, treatment resistance, and inconsistent tumor responses are some of the therapeutic issues related to thyroid cancer (TC). Chitosan-based nanoparticles (ChNPs) have shown promise as nanocarriers for target drug delivery due to their mucoadhesive qualities, biodegradability, biocompatibility, and simplicity of surface modification. Methods: With an emphasis on their role in enhancing drug delivery and targeting efficiency, this review compiled the literature on recent developments in the design, functionalization, and use of ChNPs for TC therapy. Results: According to available data, physicochemical changes such as ligand conjugation, PEGylation, and stimuli-responsive linkers can support the stability, cellular uptake, circulation time, and therapeutic efficacy of NPs. ChNPs can deliver anticancer drugs to thyroid carcinoma cells with greater selectivity by utilizing both active targeting through ligand-mediated interactions and passive targeting through the increased permeability and retention effect. When compared to traditional therapeutic methods, preclinical research has shown better boosted antitumor activity, medication absorption, and dimensioned systemic toxicity. However, difficulties with large-scale production, regulatory approval, and long-term safety evaluation continue to hinder clinical translation. Conclusion: Although further translational and clinical research is required to confirm ChNPs’ safety and efficacy in standard clinical practice, they offer a promising platform for targeted TC treatment.
Overall, this review provides a comprehensive overview of the design, synthesis, functionalization, therapeutic applications, pharmacokinetics, biodistribution, safety profiles, and clinical translation potential of folate-functionalized chitosan NPs for precision cancer therapy.
Mohammad Sameer Khan, W. Almalki· Medical Oncology· 1 citation
Pediatric brain tumors continue to be one of the leading causes of death among children due to cancer because of the inadequacies of existing treatments, which include poor tumor selectivity, poor permeability across the blood-brain barrier, resistance to treatment, and high levels of side effects on developing tissu...
Tamoxifen remains a cornerstone in the treatment of estrogen receptor-positive breast cancer, yet its clinical performance is limited by poor aqueous solubility, high lipophilicity, and interindividual variability associated with CYP2D6-mediated formation of its more potent active metabolites. These challenges necessit...
This review provides an overview of nanoparticle-based targeted drug delivery in cancer therapy, with emphasis on passive and active targeting mechanisms, major nanoparticle platforms, therapeutic applications, current challenges, and prospects for clinical translation.
G. Patil, Kartik Parmar, Kavita Rana· Journal of Drug Delivery and...· 0 citations
In conclusion, while nanocarriers offer significant advancements in targeted cancer therapy, their successful clinical implementation depends on overcoming various scientific, technical, and regulatory challenges.
Busayo Olamide Tomoh· International Journal of Med...· 0 citations
Background: Biodegradable polymeric nanoparticles have emerged as a promising platform for enhancing cancer therapy by enabling targeted drug delivery to tumor sites. The ability to manipulate the chemical and physical properties of these polymers allows them to overcome various biological barriers and achieve site-spe...
Shalini Yadav, Saket Manali Rai, S. Chandel· International Journal of Cur...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.